NIH BLUEPRINT NEUROTHERAPEUTICS NETWORK (BPN) MEDICINAL CHEMISTRY SUPPORT PROGRAM (MCSP)

NIH 蓝图神经治疗网络 (BPN) 药物化学支持计划 (MCSP)

• 批准号: 10285340
• 负责人: KEITH BARNES
• 金额: $ 27.01万
• 依托单位: ALBANY MOLECULAR RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-24 至 2021-02-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10285340
• 关键词: Biological; Cognitive deficits; Contracts; Data; Development; Epilepsy; Evaluation; Excretory function; Goals; Grant; Health; Human; In Vitro; Individual; Institutes; Intellectual Property; Investigational Drugs; Investigational New Drug Application; Lead; Legal patent; Logistics; Metabolism; Pharmaceutical Chemistry; Phase; Preparation; Property; Regulation; Research Personnel; Rights; Services; Shipping; Stroke; Toxicology; Treatment Efficacy; United States Dept. of Health and Human Services; United States National Institutes of Health; Universities; absorption; direct application; indexing; lead candidate; lead optimization; nervous system disorder; novel; novel therapeutics; pre-clinical; programs; small molecule; therapeutic development

The National Institute on Neurological Disorders and Stroke (NINDS) and the NIH Blueprint Neurotherapeutics Network (BPN) http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm have a need for the Medicinal Chemistry Support Program (MCSP) to provide a full-service facility and staff who would support a medicinal chemistry program in the late Lead Optimization phase to provide in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET) support to characterize top lead candidates to determine best preclinical candidate and to provide compound logistics of storage and shipping to support the Contributor (Dingledine, Emory University) to develop a novel therapeutic effective in cognitive deficits/epilepsy. This will be achieved by advancing the SPR of their small molecule heterocyclic starting compound utilizing in vitro ADMET to identify novel to differentiate top lead compounds. Candidate molecules have undergone some profiling related to the physicochemical properties and biological activity. The goal is to advance the project to go/no go decision amongst the top compounds provided by the Contributor. The data generated from this contract will be used by NINDS, contributors or sponsored investigators in support of Investigational New Drug (IND) application directed preclinical activities. The results of the efforts of this contract will be the basis to advance preclinical candidate compounds for further development i.e., advanced PK and toxicological evaluation in preparation of IND filings.

美国国家神经疾病和中风研究所 (NINDS) 和 NIH 蓝图 神经治疗网络（BPN）http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm 有需要 为药物化学支持计划 (MCSP) 提供全方位服务的设施和工作人员 支持后期先导物优化阶段的药物化学计划，以提供体外吸收， 分布、代谢、排泄和毒理学 (ADMET) 支持，以表征主要候选药物 确定最佳临床前候选人并提供存储和运输的复合物流支持 贡献者（Dingledine，埃默里大学）开发一种有效认知认知的新型疗法 缺陷/癫痫。这将通过推进小分子杂环起始的 SPR 来实现 利用体外 ADMET 来识别新化合物以区分顶级先导化合物。候选人 分子已经经历了一些与物理化学特性和生物特性相关的分析 活动。目标是在由以下机构提供的顶级化合物中推进项目的进行/不进行决策 贡献者。本合同生成的数据将由 NINDS、贡献者或赞助商使用 支持研究性新药 (IND) 申请的研究人员指导临床前活动。这 该合同的努力结果将成为推进临床前候选化合物的基础 进一步开发，即在准备 IND 申请时进行高级 PK 和毒理学评估。